Full-Time

Finance Strategy and Cross-Organization Excellence Lead

Deadline 7/30/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$210k - $303.3k/yr

Cambridge, MA, USA + 1 more

More locations: Morristown, NJ, USA

In Person

US and Puerto Rico residents only.

Category
Business & Strategy (1)
Required Skills
Power BI
Data Analysis
Financial Modeling
Requirements
  • 15+ years of progressive experience in finance, strategy, business transformation, or program management, with demonstrated progression into senior strategic leadership roles.
  • Proven track record of leading enterprise-level, cross-functional strategic initiatives with measurable and significant business impact across multiple organizational dimensions.
  • Demonstrated experience in product launch strategy, including financial modeling, investment planning, and cross-functional launch coordination in a commercial biopharmaceutical or healthcare context.
  • Deep expertise in portfolio strategy, pipeline planning, and capital allocation within a complex, multi-franchise business environment.
  • Experience working transversally across Commercial, M&A, Business Development, and Investor Relations functions, with the ability to integrate diverse strategic inputs into coherent financial frameworks.
  • Exceptional executive communication and stakeholder management skills, with a demonstrated ability to influence C-suite and senior leadership and to simplify highly complex strategic issues into clear, actionable recommendations.
  • Strong advanced financial modeling and quantitative analysis capabilities, including scenario modeling, valuation, and competitive benchmarking.
  • Experience operating within a global, matrixed organization with significant cross-cultural and cross-geographic complexity.
  • Bachelor's degree in Finance, Business, Economics, or a related field; MBA or advanced degree strongly preferred.
Responsibilities
  • Serve as a senior strategic advisor to the Global Head of Finance, Specialty Care, providing data-driven insights, scenario analyses, and strategic recommendations that directly inform executive decision-making.
  • Support the development and annual refresh of the Specialty Care long-range strategic plan (LRP), integrating financial modeling, pipeline assumptions, competitive dynamics, and market evolution across all therapeutic franchises.
  • Represent Finance in senior leadership forums.
  • Synthesize complex, multi-dimensional business challenges into clear strategic options and executive-ready recommendations, enabling faster and higher-quality decisions at the leadership level.
  • Proactively identify emerging strategic risks and opportunities — including competitive threats, regulatory shifts, and macroeconomic trends — and translate them into actionable financial and operational responses.
  • Support the financial and strategic architecture for new product and new indication launches across Specialty Care's therapeutic portfolio, partnering with Commercial, M&A, and Regulatory to ensure launch readiness from a strategic and financial perspective.
  • Partner with Investor Relations (IR) to ensure narratives are financially coherent, externally credible, and aligned with guidance commitments.
  • Support launch performance dashboards
  • Act as the strategic connective tissue across Specialty Care (SPC), Mergers & Acquisitions (M&A), Business Development (BD), and Investor Relations (IR), ensuring that strategies developed within each function are financially integrated, mutually reinforcing, and aligned to the overall Specialty Care ambition.
  • Lead transversal strategic initiatives that span multiple SPC franchises, driving coherence across Immunology, Rare Disease, Rare Blood Disorders, and Neurology in areas such as resource allocation, operating model design, and shared capability investment.
  • Partner with IR to develop the financial narrative for Specialty Care's pipeline and launch portfolio, ensuring that external communications on growth drivers, margin trajectory, and investment priorities are grounded in rigorous internal financial analysis.
  • Integrate M&A strategy into launch financial models and long-range plans, incorporating transaction landscape analysis, deal risk scenarios, and integration assumptions into investment decisions and revenue forecasts.
  • Provide strategic and financial analysis to support BD evaluation of in-licensing, partnership, and acquisition opportunities within the Specialty Care therapeutic space; develop financial frameworks for assessing strategic fit, value creation potential, and portfolio impact of BD transactions.
  • Facilitate cross-organizational strategy alignment sessions to resolve strategic tensions, prioritize competing investment demands, and build shared ownership of enterprise-level outcomes.
  • Support the Specialty Care portfolio strategy process, working with franchise heads, R&D finance, and Global Strategy to evaluate the current and future portfolio against strategic objectives, competitive positioning, and financial return thresholds.
  • Support design and implementation of portfolio scenario analyses to evaluate the financial and strategic implications of different pipeline configurations, including asset acceleration, deprioritization, or out-licensing decisions.
  • Partner and Embed M&A and BD financial modeling into the core of Specialty Care's strategic planning processes, ensuring that potential transactions and integration strategies are evaluated through a rigorous financial lens.
  • Ensure advanced financial models that support strategic decision-making across the full range of Specialty Care's business activities, including launch planning, portfolio prioritization, M&A evaluation, and operating model design.
  • Ensure capital allocation optimization models help leadership allocate OPEX and investment resources across franchises, geographies, and functions in a way that maximizes strategic value and financial return.
  • Lead end-to-end delivery of strategic finance initiatives, from problem definition and business case development through implementation and measurable value realization.
  • Drive efficiency and ROI initiatives as an immediate priority, identifying, designing, and executing cost reduction, productivity, and process optimization opportunities across Specialty Care.
  • Identify $50M+ of OPEX savings in Year 1; 90% SPC adherence to BO processes/guidelines (i.e., meetings and events, GTMC).
  • Identify an additional $25M+ in Year 2 through portfolio rationalization and operating model optimization.
  • Translate competitive intelligence and market evolution into strategic financial implications, quantifying the potential revenue and margin impact of competitive entries, label expansions, or pricing actions on Specialty Care's portfolio.
  • Champion the digital transformation of Specialty Care Finance, identifying and prioritizing opportunities to leverage advanced analytics, AI/ML, automation, and digital tools to enhance the quality, speed, and strategic value of financial analysis and reporting.
  • Develop a Finance Innovation Roadmap for Specialty Care, outlining a multi-year vision for how digital capabilities will transform the finance function's operating model and strategic contribution.
  • Partner with Global Digital, and enabling functions to accelerate adoption of new finance technologies, including Power BI, predictive analytics platforms, and process automation tools.
  • Establish innovation governance frameworks that ensure digital investments in Finance are prioritized based on strategic value, implementation feasibility, and measurable ROI.
  • Lead change management efforts associated with digital transformation, ensuring that finance teams across Specialty Care develop the capabilities and mindsets needed to operate effectively in a digitally enabled environment.
  • Establish robust project governance frameworks, KPIs, dashboards, and measurement systems to ensure transparency, accountability, and effective decision-making across the strategic project portfolio.
  • Partner with finance leadership and key business stakeholders to define and prioritize the project portfolio aligned with strategic and operational objectives.
  • Collaborate across Specialty Care, Global Finance, Digital, and enabling functions to accelerate adoption of new processes, tools, and technologies.
  • Champion continuous improvement and lead change management efforts to ensure sustainability of project outcomes.
  • Prepare executive-ready materials and provide regular updates to senior leadership on project progress, risks, dependencies, and financial impact.
Desired Qualifications
  • Deep expertise in biopharma commercial and launch strategy, including experience supporting multiple product launches across different therapeutic areas and geographies.
  • Familiarity with M&A economics, including transaction strategy, deal structuring, integration modeling, and outcomes-based frameworks.
  • Experience supporting Business Development and M&A transactions, including financial due diligence, valuation modeling, and post-deal integration planning.
  • Proficiency with digital finance tools (e.g., Power BI, advanced analytics platforms, AI-enabled forecasting, process automation).
  • Lean Six Sigma, PMP, or other transformation and project management certifications.
  • Experience in investor relations support, including development of financial narratives for external audiences.
  • Familiarity with competitive intelligence frameworks and strategic scenario planning methodologies.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Your Connections

People at Sanofi who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sarclisa's EU and Japan approvals should lift multiple myeloma convenience adoption.
  • Efdoralprin alfa strengthens Sanofi's rare-disease respiratory pipeline after promising Phase 2 data.
  • Owkin and Snowflake partnerships can accelerate target identification and operational productivity.

What critics are saying

  • Dupixent concentration exposes Sanofi to biosimilar pressure and payer renegotiation.
  • Riliprubart's halted Phase 3 trial signals meaningful neurology pipeline execution risk.
  • Late-stage readouts across Tzield, amlitelimab, and efdoralprin alfa remain binary and capital-intensive.

What makes Sanofi unique

  • Sarclisa is the EU's first anticancer OBI therapy, expanding home administration.
  • Sanofi combines immunology-led R&D with an AI-powered drug-development operating model.
  • Dupixent, vaccines, and rare-disease programs diversify Sanofi beyond oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Novo Holdings
May 4th, 2026
Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential.

Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential. * Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and existing investors, including Novo Holdings * Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026 * WIN378 has the potential to be the first-to-market ultra long-acting anti-TSLP antibody for asthma and COPD * WIN027 is a long-acting bispecific targeting TSLP and IL-13 with best-in-disease efficacy potential Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, and Sanofi Ventures. Proceeds will significantly extend the company's cash runway and enable multiple clinical readouts in the next 12 months. Since launching in January 2025, Windward Bio has in-licensed 2 clinical-stage assets, raised $365 million, and rapidly advanced both programmes[RW1] in the clinic. WIN378, the lead programme, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression of a wide array of immunological diseases. WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody with twice-yearly dosing. The financing will accelerate the development of WIN378, which is currently being studied in the Phase 2/3 POLARIS programme in asthma. The Phase 2 dose-ranging component of POLARIS is fully recruited, with initial data expected in the second half of 2026. The first Phase 3 study of WIN378 is expected to begin in the fourth quarter of 2026. The Phase 2 SIRIUS study in chronic obstructive pulmonary disease (COPD) is anticipated to start in the second quarter of 2026. WIN027, the second programme, is a highly potent, long-acting bispecific antibody targeting both TSLP and interleukin-13 (IL-13) - two well-validated and synergistic drivers of inflammation in severe asthma, COPD, and atopic dermatitis. WIN027 is currently in a Phase 1 study with data readout expected by the end of 2026. The financing will support multiple proof-of-concept studies across respiratory and dermatology indications starting in in the fourth quarter of 2026. "We are excited to expand our shareholder base of top-tier investors to include RA Capital, Janus Henderson, and Sanofi Ventures" said Luca Santarelli, MD, Founder, Chief Executive Officer, and Board Chair of Windward Bio. "This financing further strengthens our balance sheet and allows us to further advance our programmes of next-generation therapies for patients living with serious respiratory and dermatological diseases." Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, said: "Spearheaded by a highly experienced clinical and commercial leadership consisting of serial entrepreneurs, Windward Bio has made rapid progress since it launched in 2025, including bringing in a second clinical stage asset, WIN027. There is much more to be done towards improving dosing frequency and outcomes for the benefit of patients suffering from serious and chronic immunological conditions, and as a significant shareholder, we are pleased to support Windward Bio as it advances its innovative and developing pipeline into late-stage trials." About WIN378 WIN378 is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. WIN378 has been engineered to achieve half-life extension (HLE) and to have a silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 from Kelun Biotech (also known as SKB378) and Harbour BioMed (also known as HBM9378). WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. A Phase 2 study in COPD is anticipated to begin in the second quarter of 2026. About WIN027 WIN027 is a potential best-in-class, humanised bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, well-validated targets in immunological conditions. It has been engineered to achieve an extended half-life and enable less frequent dosing. Through this dual, long-acting inhibition, WIN027 is designed to set a new standard of efficacy in conditions such as asthma, COPD, and atopic dermatitis, potentially delivering deeper and more durable disease control than existing biologics. WIN027 is currently in Phase 1. Windward Bio licensed the global rights (excluding Greater China) for WIN027 from Qyuns Therapeutics (also known as QX027N). About Windward Bio Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead programme is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Media Enquiries Marie-Louise Jersin, Senior Communications Lead, [email protected]

Yahoo Finance
Apr 13th, 2026
Dupixent approved in EU as first targeted medicine for chronic spontaneous urticaria in children aged 2-11

Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years. The approval applies to patients with inadequate response to histamine-1 antihistamines who are naïve to anti-immunoglobulin E therapy. This expands Dupixent's existing EU approval for CSU, which previously covered adults and adolescents aged 12 and older. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. The approval is based on data from the LIBERTY-CUPID clinical trial programme, including efficacy data extrapolated from two Phase 3 adult trials and pharmacokinetic, safety and efficacy data from the CUPIDKids Phase 3 trial in children aged 2 to 11.

The Associated Press
Apr 13th, 2026
EU approves Sanofi and Regeneron's Dupixent as first targeted medicine for young children with chronic urticaria

The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years with inadequate response to antihistamines. Developed by Sanofi and Regeneron, this marks the first targeted medicine for young children with the condition in the EU. The approval, based on the LIBERTY-CUPID clinical study programme, expands Dupixent's CSU indication to children as young as two years. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. Clinical studies showed Dupixent significantly reduced urticaria activity, including itch and hives, compared with placebo at Week 24. Safety results were consistent with Dupixent's known profile in dermatological indications. A supplemental biologics licence application is under review in the US for the same patient population.

The Associated Press
Mar 31st, 2026
Sanofi's Rezurock approved in EU for chronic graft-versus-host disease treatment

The European Commission has granted conditional marketing authorisation for Sanofi's Rezurock (belumosudil) to treat chronic graft-versus-host disease in adults and children aged 12 years and older weighing at least 40 kg. The treatment is approved for patients when other options provide limited benefit or have been exhausted. The approval follows a positive opinion from the European Medicines Agency and is based on the ROCKstar phase 2 study, which demonstrated a 74% overall response rate. Nearly half of chronic GVHD patients require third-line treatment, yet therapeutic options have remained limited in the EU. Rezurock is already approved in 20 countries, including the US, UK and Canada. More than 20,000 patients have been treated with the medicine since its first US approval in July 2021.

Yahoo Finance
Mar 30th, 2026
Bernstein initiates Sanofi with 'outperform' rating, $123 target price

Bernstein analyst Justin Smith has initiated coverage of Sanofi with an "Outperform" rating and a price target of €110, representing 37% upside from current levels. The analyst believes the French biopharmaceutical company's new chief executive will unlock shareholder value. Sanofi appointed Belén Garijo, former CEO of Germany's Merck KGaA, as its new chief executive in February. The 65-year-old Spanish executive will take charge in late April, replacing Paul Hudson after his six-year tenure. The company says Garijo will strengthen productivity, governance and innovation capacity in research and development. Sanofi shares have declined over 4.5% since the beginning of 2025. The stock trades at a forward price-to-earnings ratio of 9.26.